GANX
Gain Therapeutics Inc
NASDAQ: GANX · HEALTHCARE · BIOTECHNOLOGY
$1.20
+2.14% today
Updated 2026-10-28
Market cap
$51.94M
P/E ratio
—
P/S ratio
255.50x
EPS (TTM)
$-0.50
Dividend yield
—
52W range
$1 – $4
Volume
0.5M
Gain Therapeutics Inc (GANX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$1.20
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.